(Q70487790)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

title

Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

author name string

A Lindemann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

P Brossart

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

K Höffken

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

M Flasshove

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

D Voliotis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

V Diehl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

G Hecker

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

H Wagner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

R Mertelsmann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

publication date

1 October 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

11 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

page(s)

307-315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf01518453

11 October 2019

exact match

0 references

cites work

Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2

1 reference

12 December 2020

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin 2 in humans

1 reference

12 December 2020

Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis

1 reference

12 December 2020

Comparative studies of human FcRIII-positive and negative natural killer cells

1 reference

12 December 2020

Recombinant interleukin 2 therapy in severe combined immunodeficiency disease

1 reference

12 December 2020

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

12 December 2020

Human eosinophils express functional interleukin 2 receptors

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

The immunotherapy of human cancer with interleukin 2: present status and future directions

1 reference

12 December 2020

Interleukins. Clinical pharmacokinetics and practical implications

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Transient expression of interleukin 2 receptors. Consequences for T cell growth

1 reference

12 December 2020

Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils

1 reference

12 December 2020

Lymphokine activated killer cells

1 reference

12 December 2020

Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens

1 reference

12 December 2020

The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures

1 reference

12 December 2020

Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01518453

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8402734%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

1 reference